Skip to content

Implant/Abutment Module Stability of Original vs Compatible Connections

Implant/Abutment Module Stability: a RCT Comparing Original vs Compatible Connections (Estabilidad Del módulo Implante/Pilar: ECA Comparando Conexiones Originales vs Compatibles).

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03524872
Enrollment
40
Registered
2018-05-15
Start date
2018-01-08
Completion date
2020-07-31
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Loss, Alveolar, Dental Implant Failure Nos

Brief summary

Together with materials and type of retention, the stability of the implant abutment connection represents one of the key factor for the success rate of an implant supported restoration. The recent diffusion of high quality and easy to use CAD/CAM systems has contributed to market launch of a number of competing companies that offer the so called clonical or compatible restorative components. Although they are claimed to be identical, the original abutments are supposed to present maximum accuracy and consequently lower microleakage. The aim of the present randomized controlled trial will be to analyze the implant abutment junction stability comparing implant-supported crowns restored with original components and compatible non-original abutments. The hypothesis is that original components will present significantly better stability than non-original abutments.

Interventions

DEVICEOriginal CAD/CAM prosthetic abutment

Original (Sweden&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.

DEVICECompatible CAD/CAM abutment

Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.

PROCEDURELocal anesthesia

Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).

Patients will be prescribed ibuprofen 600 mg three times per day for five days

Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward

DEVICEImplant placement

Dental implants (Sweden & Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.

Sponsors

University of Valencia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The devices will have the same shape and will be delivered to the surgeon unlabeled in an identical sterile envelope.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Any healthy patient scheduled for an implant-supported restoration will be considered for inclusion in this study, independently of the implant and prosthetic protocols used.

Exclusion criteria

* general medical contraindications to oral surgery (American Society of Anesthesiologist, ASA, class III or IV), * patients \<18 years of age, * smoking habit (\>10 cigarettes/day), * sites with acute infection or requiring regenerative procedures, * Full Mouth Plaque Score * Full Mouth Bleeding Score \>25 %, * pregnant and lactating.

Design outcomes

Primary

MeasureTime frameDescription
Biological complications1 yearProportion of cases with peri-implant disease.
Biomechanical complications1 yearProportion of cases with fracture or loosening of screws

Secondary

MeasureTime frameDescription
Microbial loads1 yearQuantitative analysis of microbial species will be studied using Illumina protocol for 6S ribosomal RNA
Probing Pocket Depth1 yearMeasured from the mucosal margin to the bottom of the probable pocket.
Modified Plaque Index1 yearPresence/absence of plaque at the cervical part of the implant-supported crown scored by running a probe along the implant-supported crown surface.
Bleeding on Probing1 yearPresence/absence of bleeding after probing.

Countries

Spain

Contacts

Primary ContactDavid Peñarrocha Oltra
david.penarrocha@uv.es0034649952560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026